Myriad Genetics (MYGN) Stock Forecast & Price Target

$27.65

-0.20 (-0.72%)

(As of 07/26/2024 ET)

Myriad Genetics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 10 Analyst Ratings

Based on 10 Wall Street analysts who have issued ratings for Myriad Genetics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 10 analysts, 2 have given a sell rating, 2 have given a hold rating, and 6 have given a buy rating for MYGN.

Consensus Price Target

$25.33
-8.38% Downside

High Forecast	$35.00
Average Forecast	$25.33
Low Forecast	$14.00

According to the 10 analysts' twelve-month price targets for Myriad Genetics, the average price target is $25.33. The highest price target for MYGN is $35.00, while the lowest price target for MYGN is $14.00. The average price target represents a forecasted downside of -8.38% from the current price of $27.65.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Hold	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	5 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$25.33	$24.88	$23.17	$27.20
Forecasted Upside	-8.38% Downside	18.46% Upside	15.06% Upside	23.67% Upside

Get Myriad Genetics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

Ad WealthPress

New trading system called MSFT, NVDA & MSFT

Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.

Just follow this link here!

MYGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MYGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Myriad Genetics Stock vs. The Competition

Type	Myriad Genetics	Medical Companies	S&P 500
Consensus Rating Score	2.40	2.72	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-8.38% Downside	3,123.18% Upside	9.15% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/27/2024	Scotiabank 5 of 5 stars	S. Nam Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$29.00	+17.79%
6/3/2024	Jefferies Financial Group 2 of 5 stars		Reiterated Rating	Hold ➝ Underperform	$25.00 ➝ $20.00	-10.11%
5/13/2024	Piper Sandler 2 of 5 stars		Boost Target	Neutral ➝ Neutral	$23.00 ➝ $28.00	+9.93%
5/8/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Souda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
5/8/2024	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$25.00 ➝ $35.00	+76.95%
1/29/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$28.00 ➝ $31.00	+38.89%
12/19/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$20.00	-2.20%
12/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$23.00	+10.15%
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$28.00	+46.98%
11/7/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$17.00 ➝ $14.00	-21.30%
3/6/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight	$17.00 ➝ $24.00	+3.18%
3/3/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$25.00 ➝ $27.00	+17.39%
8/9/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$32.00	+22.75%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:08 PM ET.

MYGN Forecast - Frequently Asked Questions

What is Myriad Genetics' forecast for 2024?: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Myriad Genetics is $25.33, with a high forecast of $35.00 and a low forecast of $14.00.
Should I buy or sell Myriad Genetics stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 2 sell ratings, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
Does Myriad Genetics's stock price have much upside?: According to analysts, Myriad Genetics's stock has a predicted upside of 18.37% based on their 12-month stock forecasts.
Has Myriad Genetics been upgraded by Wall Street analysts recently?: Over the previous 90 days, Myriad Genetics's stock had 2 upgrades by analysts.
What analysts cover Myriad Genetics?: Myriad Genetics has been rated by research analysts at Jefferies Financial Group, Leerink Partnrs, Piper Sandler, Scotiabank, and SVB Leerink in the past 90 days.
Do Wall Street analysts like Myriad Genetics more than its competitors?: Analysts like Myriad Genetics less than other "medical" companies. The consensus rating for Myriad Genetics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MYGN compares to other companies.